Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents

Gengrong Lin; Glenn Pankuch; Peter C Appelbaum; Klaudia Kosowska-Shick

doi:10.1128/AAC.02932-14

Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents

Antimicrob Agents Chemother. 2014 Oct;58(10):6251-4. doi: 10.1128/AAC.02932-14. Epub 2014 Jul 14.

Authors

Gengrong Lin¹, Glenn Pankuch¹, Peter C Appelbaum¹, Klaudia Kosowska-Shick²

Affiliations

¹ Hershey Medical Center, Hershey, Pennsylvania, USA.
² Hershey Medical Center, Hershey, Pennsylvania, USA [email protected].

Abstract

Oritavancin exhibited in vitro activity against 169 strains of vancomycin-susceptible, methicillin-resistant Staphylococcus aureus (MRSA) with MICs ranging from 0.03 to 1 μg/ml and against vancomycin-intermediate MRSA (VISA; n = 29), heterogeneous vancomycin-intermediate MRSA (hVISA; n = 5), and vancomycin-resistant MRSA (n = 5) strains, with MICs ranging from 0.12 to 4 μg/ml. For 10 MRSA isolates comprising 5 VISA and 5 hVISA strains, synergy between oritavancin and gentamicin, linezolid, or rifampin was observed against most of the strains tested using a time-kill method.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology*
Drug Synergism
Glycopeptides / pharmacology*
Lipoglycopeptides
Methicillin-Resistant Staphylococcus aureus / drug effects*
Microbial Sensitivity Tests

Substances

Anti-Bacterial Agents
Glycopeptides
Lipoglycopeptides
oritavancin